BSE and BCOS Guideline.pdf (1.43 MB)
Download file

BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab

Download (1.43 MB)
journal contribution
posted on 07.05.2021, 15:46 by R Dobson, AK Ghosh, B Ky, T Marwick, M Stout, A Harkness, R Steeds, S Robinson, D Oxborough, D Adlam, S Stanway, B Rana, T Ingram, L Ring, S Rosen, C Plummer, C Manisty, M Harbinson, V Sharma, K Pearce, AR Lyon, DX Augustine
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor receptor (HER) 2-positive targeted treatment (e.g., trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.

Funding

This work was supported by National Institutes of Health grant R01 HL 118018 (Dr. Ky).

History

Citation

JACC: CardioOncology, Volume 3, Issue 1, March 2021, Pages 1-16

Author affiliation

Department of Cardiovascular Sciences

Version

VoR (Version of Record)

Published in

JACC: CardioOncology

Volume

3

Issue

1

Pagination

1 - 16

Publisher

Elsevier

issn

2666-0873

eissn

2666-0873

Acceptance date

19/01/2021

Copyright date

2021

Available date

07/05/2021

Language

English

Usage metrics

Categories

Exports